With superior sensitivity to conventional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, the Creoptix™ WAVEsystem
is driving biologics development.
Synthetic single-domain antibodies (also known as nanobodies or sybodies) could be key to the development of COVID-19 preventive treatments given their suitability for pulmonary delivery in the form of inhaled nanobody formulations
. Using the WAVEsystem, the group of Prof. Markus Seeger
at the University of Zurich recently identified six unique sybodies with favourable binding affinity to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. In agreement with ELISA data – yet providing on- and off-rates for more kinetic details – our GCI technology
revealed that co-injection of a pair of 2 sybodies results in a clear increase of the response signal, suggesting a simultaneous binding to RBD, characteristic of non-overlapping binders.
Discover how Prof. Seeger’s in vitro selection platform was used to select sybodies from three large combinatorial libraries in twelve (12) days, and how the WAVEsystem shed light on the best candidates in just two days here.
We’ve extended this study in TechNote 14: Shedding light on sybodies binding onto SARS-CoV-2 spike RBD, carried out in collaboration with leadXpro and the University of Zurich. Discover how the WAVEsystem can be used to understand the dynamics of a sybody binding onto the receptor binding domain (RBD) region of the SARS-CoV-2 Spike protein. With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, the WAVE is accelerating the development of therapeutics against SARS-CoV-2. Read all about it here.